DE

563.11

+1.22%↑

FDX

356.21

+4.24%↑

CTAS

169.07

+0.12%↑

HEICO

273.76

+3.63%↑

PAYX

92.09

-1.04%↓

DE

563.11

+1.22%↑

FDX

356.21

+4.24%↑

CTAS

169.07

+0.12%↑

HEICO

273.76

+3.63%↑

PAYX

92.09

-1.04%↓

DE

563.11

+1.22%↑

FDX

356.21

+4.24%↑

CTAS

169.07

+0.12%↑

HEICO

273.76

+3.63%↑

PAYX

92.09

-1.04%↓

DE

563.11

+1.22%↑

FDX

356.21

+4.24%↑

CTAS

169.07

+0.12%↑

HEICO

273.76

+3.63%↑

PAYX

92.09

-1.04%↓

DE

563.11

+1.22%↑

FDX

356.21

+4.24%↑

CTAS

169.07

+0.12%↑

HEICO

273.76

+3.63%↑

PAYX

92.09

-1.04%↓

Search

John Wiley & Sons Inc

Закрыт

СекторПромышленность

0

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

Макс.

Ключевые показатели

By Trading Economics

Доход

-15M

30M

Продажи

-12M

410M

P/E

Средняя по отрасли

12.927

57.257

Дивидендная доходность

3.92

Рентабельность продаж

7.238

Сотрудники

5,200

EBITDA

-202K

105M

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

3.92%

2.27%

Следующий отчет о доходах

16 июн. 2026 г.

Дата следующей выплаты дивидендов

23 апр. 2026 г.

Следующая эксдивидендная дата

7 апр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

294M

1.9B

Предыдущая цена открытия

0

Предыдущая цена закрытия

0

Новостные настроения

By Acuity

50%

50%

187 / 405 Рейтинг в Industrials

John Wiley & Sons Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

31 мар. 2026 г., 23:31 UTC

Популярные акции

Stocks to Watch: Nike, RH, NCino

31 мар. 2026 г., 22:35 UTC

Отчет

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 апр. 2026 г., 00:00 UTC

Приобретения, слияния, поглощения

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 мар. 2026 г., 23:50 UTC

Приобретения, слияния, поглощения

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 мар. 2026 г., 23:43 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 мар. 2026 г., 23:33 UTC

Обсуждения рынка
Главные новостные события

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 мар. 2026 г., 23:21 UTC

Отчет

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 мар. 2026 г., 23:14 UTC

Обсуждения рынка
Отчет

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 мар. 2026 г., 23:12 UTC

Обсуждения рынка

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke 2025 Loss Widens >000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 мар. 2026 г., 22:36 UTC

Отчет

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 мар. 2026 г., 21:46 UTC

Приобретения, слияния, поглощения

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 мар. 2026 г., 21:36 UTC

Обсуждения рынка

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 мар. 2026 г., 21:35 UTC

Отчет

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 мар. 2026 г., 21:35 UTC

Отчет

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 мар. 2026 г., 21:35 UTC

Отчет

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 мар. 2026 г., 21:33 UTC

Приобретения, слияния, поглощения

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 мар. 2026 г., 21:33 UTC

Отчет

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 мар. 2026 г., 21:32 UTC

Отчет

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 мар. 2026 г., 21:28 UTC

Отчет

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 мар. 2026 г., 21:26 UTC

Отчет

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 мар. 2026 г., 21:25 UTC

Отчет

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 мар. 2026 г., 21:24 UTC

Обсуждения рынка
Отчет

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 мар. 2026 г., 21:22 UTC

Отчет

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 мар. 2026 г., 21:22 UTC

Отчет

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 мар. 2026 г., 21:21 UTC

Отчет

Nike's Digital Channel Still Too Promotional, CFO Says

31 мар. 2026 г., 21:20 UTC

Отчет

Nike CEO: Converse Remains Important to Portfolio

Сравнение c конкурентами

Изменение цены

John Wiley & Sons Inc Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

0

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

187 / 405Рейтинг в Промышленность

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании John Wiley & Sons Inc

John Wiley & Sons, Inc. operates as a research and learning company worldwide. It operates through three segments: Research, Learning, and Held for Sale or Sold. The company offers scientific, technical, medical, and scholarly journals, as well as related content and services to learned societies, individual researchers, other professionals, as well as academic, corporate, and government libraries. It publishes physical sciences and engineering, health sciences, social sciences, and humanities and life sciences journals through research libraries and library consortia, and independent subscription agents, direct to professional society members, and other customers ; and operates Literatum, an online publishing platform for production and content hosting, submissions and peer review support, editorial, and copyediting services. The company also offers academic and professional products and services, including scientific, professional, education print and digital books, and digital courseware to libraries, corporations, students, professionals, and researchers through chain and online booksellers, libraries, colleges and universities, corporations, direct to consumer, websites, distributor networks, and other online applications. In addition, it provides learning, development, publishing, and assessment services to businesses and professionals; and online learning and training solutions for global corporations and small and medium-sized enterprises. John Wiley & Sons, Inc. was formerly known as John Wiley And Sons and changed its name to John Wiley & Sons, Inc. in November 1953. The company was founded in 1807 and is based in Hoboken, New Jersey.
help-icon Live chat